抗抑郁药预防首发精神病后抑郁(ADEPP):多中心、双盲、随机对照试验研究方案
ADEPP 试验为多中心、双盲、随机、安慰剂对照临床研究,计划招募 452 名 18 至 65 岁、首发精神病治疗起始 12 个月内的参与者,随机接受舍曲林 50 mg 每日一次或匹配安慰剂治疗 6 个月,同时照常治疗。主要结局为 6 个月干预期内治疗组与安慰剂组新发抑郁病例数的比较,旨在评估舍曲林预防首发精神病后抑郁的疗效与成本效果。
要点
- 首发精神病后抑郁常见,影响超过 40% 的患者,增加个体负担与不良结局。
- ADEPP 试验计划招募 452 名首发精神病治疗起始 12 个月内的 18 至 65 岁患者。
- 参与者随机接受舍曲林 50 mg 每日一次或匹配安慰剂治疗 6 个月,同时照常治疗。
核心结论
- ADEPP 试验将检验首发精神病后加用舍曲林是否为改善结局的临床有用、可接受且成本有效的方法。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照临床试验,招募目标为 452 名 18 至 65 岁、首发精神病治疗起始 12 个月内的参与者。
- 参与者随机接受舍曲林 50 mg 每日一次或匹配安慰剂治疗 6 个月,同时照常治疗。
主要发现
- 主要结局为 6 个月干预期内治疗组与安慰剂组新发抑郁病例数的比较。
- 次要结局包括自杀行为、焦虑、复发率、功能结局、生活质量和资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depressive episodes are common after first-episode psychosis (FEP), affecting more than 40% of people, adding to individual burden, poor outcomes, and healthcare costs. If the risks of developing depression were lower, this could have a beneficial effect on morbidity and mortality, as well as improving outcomes. Sertraline is a selective serotonin reuptake inhibitor and a common first-line medication for the treatment of depression in adults. It has been shown to be safe when co-prescribed with antipsychotic medication, and there is evidence that it is an effective treatment for depression in established schizophrenia. We present a protocol for a multi-centre, double-blind, randomised, placebo-controlled clinical trial called ADEPP that aims to investigate the efficacy and cost-effectiveness of sertraline in preventing depression after FEP. METHODS: The recruitment target is 452 participants between the ages of 18 and 65 years who are within 12 months of treatment initiation for FEP. Having provided informed consent, participants will be randomised to receive either 50 mg of sertraline daily or matched placebo for 6 months, in addition to treatment as usual. The primary outcome measure will be a comparison of the number of new cases of depression between the treatment and placebo arms over the 6-month intervention phase. Secondary outcomes include suicidal behaviour, anxiety, rates of relapse, functional outcome, quality of life, and resource use. DISCUSSION: The ADEPP trial will test whether the addition of sertraline following FEP is a clinically useful, acceptable, and cost-effective way of improving outcomes following FEP. TRIAL REGISTRATION: ISRCTN12682719 registration date 24/11/2020.
引用
- Palmer ER, Griffiths SL, Watkins B, et al. Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial. Trials. 2023. PMID: 37803384. doi:10.1186/s13063-023-07499-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。